Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT01564056

Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment (ASTER 70s)

Adjuvant Systemic Treatment for Oestrogen-receptor (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment. A French UNICANCER Geriatric Oncology Group (GERICO) and Breast Group (UCBG) Multicentre Phase III Trial

Sponsor: UNICANCER

Conditions Breast Cancer

Interventions CHEMOTHERAPY then HORMONOTHERAPY HORMONOTHERAPY

Updated 12 times since 2017 Last updated: Jun 21, 2025 Started: Apr 12, 2012 Primary completion: Apr 11, 2022 Completion: Mar 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Breast Cancer and is currently ongoing. UNICANCER leads this study, which shows 12 recorded versions since 2012 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Active Not Recruiting PHASE3
Jul 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE3
Sep 2024 — Jul 2025 [monthly]

Active Not Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3
Jun 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE3

▶ Show 7 earlier versions

May 2023 — Jun 2024 [monthly]

Active Not Recruiting PHASE3
May 2022 — May 2023 [monthly]

Active Not Recruiting PHASE3
Sep 2021 — May 2022 [monthly]

Active Not Recruiting PHASE3
Jan 2021 — Sep 2021 [monthly]

Active Not Recruiting PHASE3
Jun 2018 — Jan 2021 [monthly]

Active Not Recruiting PHASE3
Dec 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Jan 2017 — Dec 2017 [monthly]

Recruiting PHASE3

First recorded

Apr 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UNICANCER

Data source: UNICANCER

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albi, France , Angers, France , Arlon, Belgium , Aubenas, France , Avignon, France , Bobigny, France , Bordeaux, France , Brest, France , Brussels, Belgium , Caen, France and 61 more locations